# INVO Fertility, Inc.: overview IVF · Nasdaq · CIK 1417926 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/ivf.md) · [Financials](/companies/ivf/financials.md) · [Filings](/companies/ivf/filings.md) · [Insiders](/companies/ivf/insiders.md) Latest reported revenue: [$2.2m](/filings/0001493152-26-038528.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 14, 2026 (XBRL us-gaap:Revenues, accession 0001493152-26-038528). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [1,433](/filings/0001493152-24-046822.md) | [1,715 d](/filings/0001641172-25-006726.md) | [1,642](/filings/0001641172-25-011710.md) | [1,864](/filings/0001493152-26-038528.md) | [1,757](/filings/0001493152-25-023751.md) | [1,583 d](/filings/0001493152-26-026775.md) | [2,015](/filings/0001493152-26-029514.md) | [2,175](/filings/0001493152-26-038528.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(90.7%)](/filings/0001493152-25-023751.md) | [(114.7%) d](/filings/0001493152-26-026775.md) | [(73.1%)](/filings/0001493152-26-029514.md) | [(160.4%)](/filings/0001493152-26-038528.md) | [(93.1%)](/filings/0001493152-25-023751.md) | [(89.2%) d](/filings/0001493152-26-026775.md) | [(78.9%)](/filings/0001493152-26-029514.md) | [(59.3%)](/filings/0001493152-26-038528.md) | | Net margin | % | [(113.8%)](/filings/0001493152-25-023751.md) | [(220.8%) d](/filings/0001493152-26-026775.md) | [(1060.1%)](/filings/0001493152-26-038528.md) | [(194.2%)](/filings/0001493152-26-038528.md) | [(193.3%)](/filings/0001493152-26-026775.md) | [69.2% d](/filings/0001493152-26-026775.md) | [(274.9%)](/filings/0001493152-26-038528.md) | [40.9%](/filings/0001493152-26-038528.md) | | Diluted EPS | $ per share | [(15.11)](/filings/0001493152-25-023751.md) | not reported | [(3473.93)](/filings/0001493152-26-029514.md) | [(364.23)](/filings/0001493152-26-038528.md) | [(39.40)](/filings/0001493152-26-026775.md) | not reported | [(3.38)](/filings/0001493152-26-029514.md) | [0.35](/filings/0001493152-26-038528.md) | | Free cash flow | $k | [(641) d](/filings/0001493152-25-023751.md) | [(696) d](/filings/0001493152-26-026775.md) | [(3,560)](/filings/0001493152-26-029514.md) | [(1,726) d](/filings/0001493152-26-038528.md) | [(1,785) d](/filings/0001493152-25-023751.md) | [13.4 d](/filings/0001493152-26-026775.md) | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [4,160](/filings/0001493152-23-012532.md) | [822](/filings/0001493152-24-046808.md) | [3,021](/filings/0001641172-25-006726.md) | [6,561](/filings/0001641172-25-006726.md) | [6,841](/filings/0001493152-26-026775.md) | | Gross margin | % | [96.5%](/filings/0001493152-23-012532.md) | [59.7%](/filings/0001493152-23-012532.md) | not reported | not reported | not reported | | Operating margin | % | [(125.4%)](/filings/0001493152-23-012532.md) | [(1292.5%)](/filings/0001493152-24-046808.md) | [(224.0%)](/filings/0001641172-25-006726.md) | [(101.0%)](/filings/0001493152-26-026775.md) | [(105.8%)](/filings/0001493152-26-026775.md) | | Net margin | % | [(160.0%)](/filings/0001493152-23-012532.md) | [(1324.8%)](/filings/0001493152-24-046808.md) | [(266.0%)](/filings/0001641172-25-006726.md) | [(141.1%)](/filings/0001493152-26-026775.md) | [(340.9%)](/filings/0001493152-26-026775.md) | | Diluted EPS | $ per share | [(0.63)](/filings/0001493152-23-012532.md) | [(17.97)](/filings/0001493152-24-046808.md) | [(67.37)](/filings/0001641172-25-006726.md) | [(3782.65)](/filings/0001493152-26-026775.md) | [(214.64)](/filings/0001493152-26-026775.md) | | Free cash flow | $k | [(6,446)](/filings/0001493152-23-012532.md) | [(6,614)](/filings/0001493152-24-046808.md) | [(5,200)](/filings/0001641172-25-006726.md) | [(3,158)](/filings/0001493152-26-026775.md) | [(7,058)](/filings/0001493152-26-026775.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ivf/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Scientech Research LLC](/funds/2011556.md) | 2026-06-30 | $61.4k | 32,338 | | New +32,338 | | [StoneX Group Inc.](/funds/913760.md) | 2026-06-30 | $29.8k | 15,702 | | New +15,702 | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $21.8k | 11,463 | | New +11,463 | | [Tower Research Capital LLC (TRC)](/funds/1533421.md) | 2026-06-30 | $15.5k | 8,155 | | New +8,155 | | [Virtu Financial LLC](/funds/1533964.md) | 2026-06-30 | $120 | 63,174 | | New +63,174 | | [SBI Securities Co., Ltd.](/funds/1851815.md) | 2026-06-30 | $101 | 53 | | Added +50 | | [Caitong International Asset Management Co., Ltd](/funds/1963355.md) | 2026-06-30 | $72 | 38 | | New +38 | | [Integrated Wealth Concepts LLC](/funds/1737109.md) | 2026-06-30 | $15 | 8 | | New +8 | | [DANSKE BANK A/S](/funds/800177.md) | 2026-06-30 | $2 | 1 | | New +1 | ## Recent filings [All 584 filings](/companies/ivf/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-28 | 12:30 ET | [8-K](/filings/0001493152-26-040504.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-040504 | | 2026-08-17 | 12:35 ET | [8-K](/filings/0001493152-26-038648.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001493152-26-038648 | | 2026-08-14 | 21:27 ET | [10-Q](/filings/0001493152-26-038528.md) | Quarterly report, period 2026-06-30 | 0001493152-26-038528 | | 2026-07-24 | 21:20 ET | [S-1](/filings/0001493152-26-034621.md) | Registration statement | 0001493152-26-034621 | | 2026-07-24 | 21:14 ET | [8-K](/filings/0001493152-26-034616.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001493152-26-034616 | | 2026-06-25 | 20:52 ET | [8-K](/filings/0001493152-26-030147.md) | 1.01 Entry into a material agreement; 8.01 Other events | 0001493152-26-030147 | | 2026-06-23 | 20:05 ET | [DEF 14A](/filings/0001493152-26-029785.md) | Proxy statement, period 2026-06-23 | 0001493152-26-029785 | | 2026-06-22 | 13:05 ET | [8-K](/filings/0001493152-26-029517.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001493152-26-029517 | | 2026-06-22 | 13:00 ET | [10-Q](/filings/0001493152-26-029514.md) | Quarterly report, period 2026-03-31 | 0001493152-26-029514 | | 2026-06-16 | 21:00 ET | [8-K](/filings/0001493152-26-028910.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-028910 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001493152-26-026775.md), filed Jun 2, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/4ca38d2b-6372-4ea6-922a-b2a9b5f44f5a) ## About the filer - CIK: 1417926 - Tickers: IVF - Exchange: Nasdaq - SIC code: 3841 Surgical & Medical Instruments & Apparatus - State of incorporation: NV - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:39 ET. No prices; not investment advice.